Skip to main content

Advertisement

SpringerLink
Log in

Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

A 60-year-old woman was admitted to a medical clinic because of epigastric pain. Esophagogastroduodenoscopy revealed a submucosal tumor in the upper gastric corpus and, the tumor was subsequently resected using partial gastrectomy. The pathological findings revealed that the tumor was a gastrointestinal stromal tumor. After 4 months of observation without any adjuvant treatment, the patient was found to have liver metastasis and she was admitted to our hospital for treatment. We successfully treated the patient through sequential drug therapies, including imatinib, nilotinib, sunitinib, and regorafenib, and maintaining disease control for more than 5 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Cancer Netw 8(Suppl 2):S1–S41 (quiz S42–44)

    CAS  Google Scholar 

  2. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

    Article  CAS  PubMed  Google Scholar 

  3. Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625

    Article  CAS  PubMed  Google Scholar 

  4. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  CAS  PubMed  Google Scholar 

  5. Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302

    Article  CAS  PubMed  Google Scholar 

  6. Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419

    Article  PubMed  Google Scholar 

  7. Rutkowski P, Bylina E, Wozniak A et al (2011) Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37:890–896

    Article  CAS  PubMed  Google Scholar 

  8. Blay JY, Shen L, Kang YK et al (2015) Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 16:550–560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  10. Sawaki A, Nishida T, Doi T et al (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117:4633–4641

    Article  CAS  PubMed  Google Scholar 

  11. Kang YK, Ryu MH, Yoo C et al (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14:1175–1182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774

    Article  CAS  PubMed  Google Scholar 

  13. Komatsu Y, Doi T, Sawaki A et al (2015) Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol 20:905–912

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Medical Oncology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

      Shunsuke Sugiyama, Masanobu Takahashi, Keigo Komine, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Shin Takahashi, Hideki Shimodaira & Chikashi Ishioka

    2. Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan

      Shunsuke Sugiyama, Masanobu Takahashi, Keigo Komine, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Shin Takahashi, Hideki Shimodaira & Chikashi Ishioka

    3. Tohoku University School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan

      Mariko Ishizuka

    Authors
    1. Shunsuke Sugiyama
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Mariko Ishizuka
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Masanobu Takahashi
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Keigo Komine
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Hiroo Imai
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Ken Saijo
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Masahiro Takahashi
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Hidekazu Shirota
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Shin Takahashi
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Hideki Shimodaira
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Chikashi Ishioka
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Chikashi Ishioka.

    Ethics declarations

    Conflict of interest

    C. Ishioka reports receiving lecture fees from Taiho, Chugai, Takeda, Beyer, Pfeizer, Mochida, Asahikasei, Bristol-Myers Squibb, Daiichi-Sankyo, Merck Serono, and Novartis, and grant support from Chugai, Taiho, Bristol-Myers Squibb, Daiichi-Sankyo, Merck Serono, Yakult, Ono, and Novartis.

    Research involving Human Participants and/or Animals

    This article does not contain any studies with human participants performed by any of the authors.

    Informed consent

    Informed consent was obtained from the patient for the publication of the report that describes her case.

    Additional information

    S. Sugiyama and M. Ishizuka have contributed equally to this work.

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Sugiyama, S., Ishizuka, M., Takahashi, M. et al. Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs. Int Canc Conf J 5, 163–167 (2016). https://doi.org/10.1007/s13691-016-0250-1

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13691-016-0250-1

    Keywords

    Search

    Navigation